Table 1

Baseline characteristics of patients and of VTE events

n (%)DOAC cohort
2170 (79.5)
VKA cohort
558 (20.5)
P value
Male, n (%)1115 (51.4)269 (48.2)NS
Age, median (IQR), years68 (52–78)69 (53–79)NS
Age classes, n (%)
 <65 years975 (44.9)236 (42.3)NS
 65–74 years503 (23.2)130 (23.3)NS
 ≥75 years692 (31.9)192 (34.4)NS
Creatinine, mg/dL, median (IQR)0.90 (0.76–1.0)0.90 (0.75–1.1)NS
Creatinine >1.5 mg/dL, n (%)63 (2.9)45 (8.1)<0.001
Creatinine clearance, n (%)
 <30 mL/min32 (1.5)32 (5.7)<0.001
 30–59 mL/min493 (22.7)148 (26.5)NS
 60–90 mL/min741 (34.1)179 (32.1)NS
 >90 mL/min890 (41.0)199 (35.7)0.023
 Missing14 (0.7)
Type of VTE event, n (%)
 DVT1331 (61.3)280 (50.2)<0.001
 Proximal1006 (75.6)175 (62.5)<0.001
 Distal277 (20.8)100 (35.7)<0.001
 Missing48 (3.6)5 (1.8)
 DVT+PE460 (21.2)147 (26.3)0.01
 Proximal+PE373 (81.1)95 (64.6)<0.001
 Distal+PE73 (15.9)48 (32.7)<0.001
 Missing14 (3.0)4 (2.7)NS
 Isolated PE379 (17.5)131 (23.5)0.001
Nature of VTE events, n (%)
 Idiopathic1429 (65.9)394 (70.6)0.035
 Associated with weak RF105 (4.8)36 (6.5)NS
 Provoked by transient major RF360 (16.6)72 (12.9)0.033
 Provoked by permanent major RF264 (12.2)49 (8.8)0.025
 Cancer94 (35.6)31 (63.3)0.001
 Missing12 (0.6)7 (1.3)NS
 Charlson’s score, median (IQR)3 (2–5)4 (2–6)0.0001
 Associated antiplatelet agents, n (%)138 (6.4)53 (9.5)0.011
DOAC, all n=2170; low dose, 266 (12.3%)Total
n (%)
Standard dose
n (%)
Low dose
n (%)
 Rivaroxaban (20 mg or 15 mg once daily)*1317 (60.7)1245 (57.4)72 (3.3)
 Apixaban (5 mg or 2.5 mg two times per day)501 (23.1)383 (17.6)118 (5.4)
 Dabigatran (150 mg or 110 mg two times per day)189 (8.7)157 (7.2)32 (1.5)
 Edoxaban (60 mg or 30 mg once daily)163 (7.5)119 (5.5)44 (2.0)
  • *The use of rivaroxaban 10 mg per day for extended VTE treatment was approved by Italian Health System Authorities (AIFA) and reimbursed only in March 2019 (not available at the time of the present study).

  • DOAC, direct oral anticoagulant; DVT, deep vein thrombosis; NS, not statistically significant; PE, pulmonary embolism; RF, risk factors; VKA, vitamin K antagonist; VTE, venous thromboembolism.